Pharmacosmos introduces DEAE-Dextran

Holbæk, Denmark, July 14, 2015 - Pharmacosmos has introduced DEAE-Dextran as part of the company's extensive array of biopolymers for pharmaceutical use. The company sees the introduction as part of a dedicated continuing effort to developing and supplying its customers with high quality dextran derivatives.

"Our DEAE-Dextran is graced with the same high quality as our other dextran derivatives, and we believe that we by introducing DEAE-Dextran as part of our already extensive portfolio are able to build an even stronger position in the market," said Dr Lars Christensen, CEO at Pharmacosmos.

Pharmacosmos is a world leader in pharmaceutical dextran solutions and counts tailor-made solutions to special carbohydrate needs among its forces. The company is the only dextran provider approved by the US FDA and EDQM in Europe, and Pharmacosmos operates on the basis of an innovative and unique manufacturing process without the use of organic solvents.

Dextran is used in a number of areas, among other ophthalmic, vaccines, cryopreservation, lyophilization and volume expansion.

About Pharmacosmos
Pharmacosmos develops and markets iron carbohydrates for the treatment of iron deficiency. A research-based company, its ongoing R&D program focuses on improving the treatment options for healthcare professionals, patients suffering from iron deficiency and veterinary treatments. The company is a pioneer in synthesis, purification and fractionation of dextran and supply pharmaceutical quality dextran complying with the European Pharmacopoeia (EP), the US Pharmacopoeia (USP) and the Japanese Pharmacopoeia (JP). 

About Dextran and DEAE-Dextran
Dextran is used in a number of areas, among other ophthalmic, oral application/tablets, vaccines, cryopreservation, lyophilization and volume expansion.

DEAE-Dextran (Diethylaminoethyl-Dextran) is a polycatonic derivative of Dextran. DEAE-Dextran is used for a number of applications hereunder as vaccine adjuvant, in gene therapy, and protein stabilization.

For more information, please see:

Application areas

and

Products - DEAE-Dextran 500

Additional information:

Anne-Marie J. Ørklild
International Sales & Business Director, Carbohydrates
T: +45 59 48 59 86
E: amo@pharmacosmos.com
W: www.dextran.com